Effect of melatonin on gut microbiome and metabolomics in diabetic cognitive impairment
Frontiers in Pharmacology · 21.11.2024 · 15
DOI: 10.3389/fphar.2024.1489834 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 21.11.2024. Verfasst von Ming Gao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Rare Disease, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Diabetic cognitive impairment(DCI) presents as a central nervous complication of diabetes especially among aging population. Melatonin (MEL) is known for its antioxidant and anti-inflammation effects in neuroprotective aspects. Recent evidence has demonstrated that the gut microbiome plays a key role in DCI by modulating cognitive function through the gut–brain crosstalk. MEL has been shown to modulate gut microbiota composition in diabetic model. However, the underlying mechanism through which the gut microbiome contributes to DCI remains unclear. This study aims to investigate the effect and mechanism of MEL in attenuating DCI in relation to regulating the gut microbiome and metabolomics.
Methods
Cognitive and memory function were assessed by the Morris water maze test, histopathological assessment of brain tissues, and immunoblotting of neuroinflammation and apoptosis. The levels of serum tumor necrosis factor-α (TNF-α) and Interleukin-18 (IL-18) were measured by enzyme-linked immunoassays to reflect the circulatory inflammation level.16S rRNA microbiome sequencing analysis was performed on control mice(db-m group), diabetic mice(db-db group) and MEL-treated diabetic mice(db-dbMEL group). Gut metabolites changes were characterized using liquid chromatography tandem mass spectrometry (LC-MS/MS).
Results
Our study confirmed that MEL alleviated diabetes-induced cognition and memory dysfunction. MEL protected against neuroinflammation and apoptosis in hippocampus of db-db mice. MEL corrected the increased abundance of Bacteroides and Dorea and the reduced abundance of Prevotella in db-db mice. The vast majority of differential metabolites among the three groups were lipids and lipid-like molecules. MEL significantly restored the reduced levels of pyruvate and lactic acid.
Discussion
Our results supported the use of MEL as a promising therapeutic agent for DCI, in which the underlying mechanism may be associated with gut microbiome and metabolomics regulation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology and Rare Disease, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
- Hebei Key Laboratory of Rare Disease, Hebei Provincial Department of Science and Technology, Shijiazhuang, Hebei, China.
- Core Facilities and Centers, Hebei Medical University, Shijiazhuang, Hebei, China.
- Department of Neurosurgery, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Zitieren
APA
Gao, M., Li, J., Han, X., Zhang, B., Chen, J., Lang, J., & Zhang, Q. (2024). Effect of melatonin on gut microbiome and metabolomics in diabetic cognitive impairment. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1489834
Vancouver
Gao M, Li J, Han X, Zhang B, Chen J, Lang J, et al. Effect of melatonin on gut microbiome and metabolomics in diabetic cognitive impairment. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1489834
BibTeX
@article{Gao2024,
author = {Gao, Ming and Li, Jie and Han, Xu and Zhang, Beiyao and Chen, Jinting and Lang, Jiadong and Zhang, Qiangqiang},
title = {Effect of melatonin on gut microbiome and metabolomics in diabetic cognitive impairment},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1489834}
}
EUVIMED